# A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea

> **NCT02095158** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 440 (actual)

## Conditions studied

- Erythema
- Rosacea

## Interventions

- **DRUG:** Oxymetazoline HCL Cream 1.0%

## Key facts

- **NCT ID:** NCT02095158
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-08
- **Final completion:** 2015-09
- **Target enrollment:** 440 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095158, "A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02095158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*